METHOD OF TREATING TRUNCAL ACNE WITH TRIFAROTENE
Disclosed herein are methods for selectively treating acne vulgaris of the face and/or trunk in a subject, pharmaceutical compositions for use in the treatment of acne vulgaris of the face and/or trunk in a subject, uses of trifarotene or an equivalent thereof in the manufacture of a medicament for the treatment of acne vulgaris of the face and/or trunk in a subject.
1 . A method of treating acne vulgaris of the face and/or trunk in a subject in need thereof, the method comprising topically administering to the subject, a pharmaceutical composition comprising trifarotene or an equivalent thereof and a pharmaceutically acceptable carrier.
2 . The method according to claim 1 , comprising treating acne vulgaris of the trunk.
3 . The method according to claim 1 , wherein trifarotene or the equivalent thereof is administered once daily, twice daily, once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.
4 . The method according to claim 1 , wherein the pharmaceutical composition is administered to the area of the subject affected with acne vulgaris.
5 . The method according to claim 1 , wherein the pharmaceutical composition is administered once daily to the affected areas of the subject.
6 . The method according to claim 1 , wherein the pharmaceutical composition comprises from about 1 μg/g to about 100 μg/g of trifarotene or an equivalent.
7 . The method according to claim 1 , wherein the pharmaceutical composition comprises about 50 μg/g of trifarotene or an equivalent thereof.
8 . The method according to claim 1 , wherein the pharmaceutical composition is formulated as a cream.
9 . The method according to claim 1 , wherein the pharmaceutical composition is formulated as an oil-in-water emulsion.
10 . The method according to claim 1 , wherein the amount of trifarotene or the equivalent thereof administered to the subject is about 0.00001 to about 1% by weight of the pharmaceutical composition.
11 . The method according to claim 1 , wherein the treatment comprises reduction in inflammatory lesion counts of the subject.
12 . The method according to claim 1 , wherein the treatment comprises reduction in noninflammatory lesion counts of the subject.
13 . The method according to claim 1 , wherein the acne vulgaris of the face and/or trunk comprises mild, moderate and severe acne vulgaris of the face and/or trunk.
14 . The method according to claim 1 , wherein the acne vulgaris of the face and/or trunk is moderate.
15 . A pharmaceutical composition, comprising trifarotene or an equivalent thereof and a pharmaceutically acceptable carrier.
16 . The pharmaceutical composition of claim 15 , wherein the pharmaceutically acceptable carrier comprises one or more of an ointment, a cream, a gel, a spray, a foam, a paste or a suspension.
17 . The pharmaceutical composition according to claim 1 , comprising trifarotene or an equivalent thereof in an amount of from about 0.001 to about 0.1% by weight, relative to the weight of the total composition.
18 . The pharmaceutical composition according to claim 1 , comprising from about 1 μg/g to about 100 μg/g of trifarotene.
19 . The pharmaceutical composition according to claim 1 , formulated as a cream.